Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Jingfeng
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.	Recruiting	3	480	RoW	Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Hepatocellular Carcinoma	08/24	12/26
AK112-207, NCT05432492: A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)	Not yet recruiting	2	60	NA	AK112	Akeso	Hepatocellular Carcinoma	08/23	08/24
NCT05781360: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors	Terminated	1	192	US, RoW	SIM0237	Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd., Simcere Zaiming	Locally Advanced Unresectable or Metastatic Solid Tumor	05/24	05/24